Venous sinus stenting appears safe and effective for treating brain pressure caused by tumors compressing blood vessels, with two-thirds of patients experiencing symptom improvement. However, this conclusion is based on only 57 patients across 20 small studies, making definitive claims impossible at this stage.
A systematic review of 20 studies examined endovascular treatment, specifically venous sinus stenting (VSS) and angioplasty, for patients whose tumors obstruct the dural venous sinuses, the major blood vessels that drain blood from the brain. When these sinuses become blocked, fluid can accumulate in the skull, raising intracranial pressure and causing problems like vision loss and papilledema (swelling of the optic disc).
The analysis included 57 patients, predominantly women (65%) with an average age of 48 years. Meningiomas, benign brain tumors that arise from the membrane surrounding the brain, accounted for 75% of cases. In 86% of patients, the obstruction resulted from direct tumor compression or invasion of the sinus, while the remainder had stenosis following surgery or radiation therapy. Most patients (74%) received VSS alone, while 23% underwent combined VSS and angioplasty.
The technical results were measurable and consistent. The pressure gradient across the stenosis (the narrowed section) decreased by an average of 10 mmHg after intervention. Lumbar puncture measurements, which directly assess cerebrospinal fluid pressure, showed an average decrease of 11 cmH2O. Critically, the review reported zero periprocedural complications, suggesting the procedure is technically safe when performed in experienced centers.
The clinical outcomes aligned with pressure reduction. Approximately 63% of patients reported clinical improvement overall. Vision-related improvements were particularly notable: 94% of patients with vision changes at baseline showed resolution or improvement, and 94% of those with papilledema experienced similar recovery. However, durability remains a concern. Twenty-eight percent of patients required repeat intervention, and only about half of those achieved further improvement after reintervention, suggesting that restenosis occurred in a meaningful subset.
This research primarily applies to a narrow population: patients with tumor-related venous sinus obstruction causing secondary intracranial hypertension. If you fall into this category, this data suggests endovascular intervention merits serious consideration before committing to surgical resection, particularly given that VSS avoids the invasiveness and risks of open surgery.
The safety profile is the strongest takeaway. No acute complications were reported across 57 cases, which is reassuring for a procedure involving catheterization and stent placement in the brain's drainage vessels. The pressure improvements and symptom resolution rates suggest meaningful clinical benefit for most patients, though outcomes vary.
The need for repeat intervention in over one-quarter of cases indicates this is not a permanent solution for everyone. Patients should understand that symptom recurrence may occur and additional procedures might be necessary. The fact that not all reinterventions succeed adds another layer of uncertainty. This is not a criticism of the procedure, but rather reflects the limited biological durability of current endovascular approaches in this specific setting.
The evidence quality remains very low. These findings are drawn from 20 small case series and individual case reports, not randomized controlled trials. Different centers use different patient selection criteria, stent types, and follow-up protocols, making direct comparisons difficult. Larger, prospective studies are needed to establish which patient characteristics predict good outcomes and whether specific technical approaches yield better long-term results.
| Metric | Value |
|---|---|
| Study Type | Systematic Review |
| Total Patients | 57 |
| Number of Included Studies | 20 |
| Female Percentage | 65% |
| Mean Age | 48 years |
| Most Common Tumor | Meningioma (75%) |
| Primary Treatment | VSS alone (74%) |
| Periprocedural Complications | 0 |
| Clinical Improvement Rate | 63% |
| Repeat Intervention Rate | 28% |
| Mean Pressure Gradient Reduction | 10 ± 9 mmHg |
| Mean Lumbar Opening Pressure Reduction | 11 ± 12 cmH2O |
| Evidence Tier | Very Low |
| Journal | Journal of Neuro-Oncology |
Systematic review examining endovascular treatment of tumor-related dural sinus stenosis: https://pubmed.ncbi.nlm.nih.gov/42364002/
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.
| 42364002 |